MorphoSys AG (MOR)

NASDAQ: MOR · IEX Real-Time Price · USD
18.14
0.00 (0.00%)
Mar 28, 2024, 4:00 PM EDT - Market closed
0.00%
Market Cap 2.74B
Revenue (ttm) 264.75M
Net Income (ttm) -210.82M
Shares Out 150.48M
EPS (ttm) -1.49
PE Ratio n/a
Forward PE 322.58
Dividend n/a
Ex-Dividend Date n/a
Volume 274,026
Open 18.15
Previous Close 18.14
Day's Range 18.10 - 18.16
52-Week Range 3.89 - 18.31
Beta 0.61
Analysts Hold
Price Target 12.13 (-33.13%)
Earnings Date Mar 13, 2024

About MOR

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 9, 1999
Employees 524
Stock Exchange NASDAQ
Ticker Symbol MOR
Full Company Profile

Financial Performance

In 2023, MorphoSys AG's revenue was 238.28 million, a decrease of -14.37% compared to the previous year's 278.27 million. Losses were -189.73 million, 25.6% more than in 2022.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for MOR stock is "Hold." The 12-month stock price forecast is $12.13, which is a decrease of -33.13% from the latest price.

Price Target
$12.13
(-33.13% downside)
Analyst Consensus: Hold
Stock Forecasts

News

MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 22, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvement...

7 days ago - Accesswire

MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2023. “In 2023, we demonstrated the potential for pelabresib to ...

15 days ago - Business Wire

Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 7, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2023 on March 13, 2024, at 09:00 pm ...

21 days ago - Accesswire

Novartis to acquire German Biotech MorphoSys for $2.9B, Expanding Cancer Drug Pipeline

Novartis (NVS) has struck a deal to buy German biotech firm MorphoSys (MOR), a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), as the Swiss drugmaker expands its roster of cancer...

Other symbols: NVS
7 weeks ago - Investopedia

Novartis to bolster its oncology portfolio with acquisition of MorphoSys

Novartis AG on Monday announced it has agreed to buy German biopharmaceutical company MorphoSys AG for 2.7 billion euros ($2.9 billion).

Other symbols: NVS
7 weeks ago - Market Watch

Novartis acquiring cancer drug developer Morphosys for €2.7 billion

CNBC's Steve Kovach joins 'Closing Bell Overtime' with breaking news out of the pharmaceutical space.

Other symbols: NVS
7 weeks ago - CNBC Television

MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value

Tafasitamab sold to Incyte Novartis to launch a voluntary public takeover offer for all MorphoSys shares at a price of € 68.00 per share in cash Shareholders benefit from attractive premium of 94 perc...

7 weeks ago - Accesswire

Novartis acquires cancer drug developer MorphoSys for $2.9 bln

Drugmaker Novartis AG said on Monday is has acquired MorphoSys AG , a developer of cancer treatments, for 2.7 billion euros. ($2.90 billion)

Other symbols: NVS
7 weeks ago - Reuters

Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash

Basel, February 05, 2024 – Novartis today announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (FSE: MOR; NASDAQ: MOR), a Germany-based, gl...

Other symbols: NVS
7 weeks ago - GlobeNewsWire

Exclusive: Novartis in the lead to acquire cancer drug developer MorphoSys-sources

Drug maker Novartis AG is in advanced talks to acquire MorphoSys AG , a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion), two people familiar with the matter ...

Other symbols: NVS
7 weeks ago - Reuters

MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability

Preliminary 2023 Monjuvi U.S. net product sales of US$ 92.0 million (€ 85.0 million) and preliminary gross margin for Monjuvi U.S. net product sales of 69% Anticipated 2024 Monjuvi U.S. net product sa...

2 months ago - Accesswire

MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 8, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that Jean-Paul Kress, M.D., Chief Executive Officer, will present at the 42nd Annual J.P.

2 months ago - Accesswire

MorphoSys' Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET ...

3 months ago - Business Wire

MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced strong topline results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET...

4 months ago - Business Wire

MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the third quarter and the first nine months of 2023. “With pelabresib, MorphoSys has the potential to...

4 months ago - Business Wire

Invitation to MorphoSys' Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / November 9, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the third quarter and first nine months 2023 on Nove...

5 months ago - Accesswire

MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Following topline results expected in the coming weeks, the oral session at ASH 2023 in December will provide detailed findings from MANIFEST-2 Investor event focused on MANIFEST-2 with MorphoSys mana...

5 months ago - Accesswire

MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023

Preliminary Q3 2023 Monjuvi U.S. net product sales of US$ 23.4 million (€ 21.5 million) Preliminary Gross Margin for Monjuvi U.S. net product sales for Q3 2023 of 65% Anticipate full year 2023 Monjuvi...

5 months ago - Accesswire

MorphoSys shares gain as endometrial cancer treatment gets fast-track designation

MorphoSys AG's American depositary receipts MOR, +1.38% gained 2% premarket on Wednesday after the biopharma company said its investigational treatment for endometrial cancer was granted fast-track de...

7 months ago - Market Watch

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

Tulmimetostat follows pelabresib (2018) and tafasitamab (2014) as the company's third clinical program to receive Fast Track designation PLANEGG and MUNICH, GERMANY / ACCESSWIRE / September 12, 2023 /...

7 months ago - Accesswire

MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the second quarter and first half year of 2023. "With topline data from the pivotal MANIFEST-2 trial ...

8 months ago - Business Wire

MorphoSys AG Reports First Quarter 2023 Financial Results

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2023. “We had a strong first quarter, marked by numerous achievements. Most impo...

11 months ago - Business Wire

Invitation to MorphoSys' First Quarter 2023 Financial Results Conference Call on May 4, 2023

Conference Call Alert MUNICH, GERMANY / ACCESSWIRE / April 27, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the first quarter 2023 on May 3, 2023 at 10:00 pm CEST (09:00 pm B...

1 year ago - Accesswire

MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022. “2022 was a defining year for MorphoSys. We made advances ...

1 year ago - Business Wire